search
Back to results

Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography

Primary Purpose

Infertility, Pain

Status
Completed
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
Hysterosalpingography (HSG)
Placebo
Sponsored by
Universitair Ziekenhuis Brussel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring HSG, analgesia, tramadol, metal cannula, balloon catheter

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • > 18 and < 45 years
  • Written informed consent

Exclusion Criteria:

  • Contra-indication to tramadol, morphine or to other opioids

    • Concomitant use of MAO inhibitors or use less than 2 weeks prior to procedure
    • Use of any other CNS-acting drug
  • Contra-indication to radio-contrast medium (allergy)
  • Patient already taking analgetics
  • History of cervical stenosis
  • Presence of pelvic inflammatory disease or any other condition causing pelvic pain
  • Clinical and/or laboratory evidence of any major disease
  • Pregnant or lactating

Sites / Locations

  • UZ Brussel

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Arm Label

Tramadol + Metal cannula

Placebo + Metal cannula

Tramadol + Balloon

Placebo + Balloon

Arm Description

Fast-release Orodispersible Tramadol Tablet + Metal cannula

Placebo + Metal cannula

Fast-release Orodispersible Tramadol Tablet + balloon catheter

Placebo + balloon catheter

Outcomes

Primary Outcome Measures

VAS at the six different assessment points

Secondary Outcome Measures

Adverse effects and complications

Full Information

First Posted
May 4, 2009
Last Updated
May 4, 2009
Sponsor
Universitair Ziekenhuis Brussel
search

1. Study Identification

Unique Protocol Identification Number
NCT00893412
Brief Title
Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography
Official Title
Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography : a Randomized, Controlled, Double Blinded Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2009
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
April 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Universitair Ziekenhuis Brussel

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the analgetic effects of the fast-release orodispersible tramadol tablet. Tramadol acts through a weak affinity for μ receptors and secondly by inhibiting noradrenaline and serotonin neuronal reuptake. It has been used since the 1970s by over 50 million people for the treatment of acute and chronic pain. The orodispersible Tramadol tablet is a new galenic form and is available on the Belgian market for the last three years. Pregastric absorption leads to a quicker onset of action. So far, evidence shows that pain during and immediately after the Hysterosalpingography (HSG) procedure is only significantly reduced by IV opioid analgesia. This study evaluates the analgetic potential of an orodispersible opioid tablet. This tablet disintegrates rapidly (in around 20-30 seconds) and may be taken without water. Its abuse potential is very low and its respiratory depressant effect is negligible.
Detailed Description
Four arm prospective randomized double blinded trial Patients that need a HSG as part of their diagnostic work-up and are eligible for randomization are counseled about possible participation. After signing the informed consent patients will be randomized in one of the following four groups: Group 1: Fast-release Orodispersible Tramadol Tablet + metal cannula Group 2: Placebo + metal cannula Group 3: Fast-release Orodispersible Tramadol Tablet + balloon catheter Group 4: Placebo + balloon catheter Tablets are administered 30 min before the procedure Primary Endpoint: VAS at the six different assessment points Secondary Endpoint adverse effects and complications such as: nausea, vomiting, constipation, drowsiness, respiratory depression, hypotension, allergic reaction and infection

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Pain
Keywords
HSG, analgesia, tramadol, metal cannula, balloon catheter

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
128 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tramadol + Metal cannula
Arm Type
Active Comparator
Arm Description
Fast-release Orodispersible Tramadol Tablet + Metal cannula
Arm Title
Placebo + Metal cannula
Arm Type
Placebo Comparator
Arm Description
Placebo + Metal cannula
Arm Title
Tramadol + Balloon
Arm Type
Active Comparator
Arm Description
Fast-release Orodispersible Tramadol Tablet + balloon catheter
Arm Title
Placebo + Balloon
Arm Type
Placebo Comparator
Arm Description
Placebo + balloon catheter
Intervention Type
Drug
Intervention Name(s)
Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
Other Intervention Name(s)
Tradonal odis®
Intervention Description
1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
Intervention Type
Procedure
Intervention Name(s)
Hysterosalpingography (HSG)
Other Intervention Name(s)
HSG
Intervention Description
One HSG using a metal canula or balloon catheter, 30 minutes after tablet
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
VAS at the six different assessment points
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Adverse effects and complications
Time Frame
24 hours

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: > 18 and < 45 years Written informed consent Exclusion Criteria: Contra-indication to tramadol, morphine or to other opioids Concomitant use of MAO inhibitors or use less than 2 weeks prior to procedure Use of any other CNS-acting drug Contra-indication to radio-contrast medium (allergy) Patient already taking analgetics History of cervical stenosis Presence of pelvic inflammatory disease or any other condition causing pelvic pain Clinical and/or laboratory evidence of any major disease Pregnant or lactating
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul Devroey, MD, PhD
Organizational Affiliation
Universitair Ziekenhuis Brussel
Official's Role
Study Director
Facility Information:
Facility Name
UZ Brussel
City
Brussels
ZIP/Postal Code
1090
Country
Belgium

12. IPD Sharing Statement

Learn more about this trial

Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography

We'll reach out to this number within 24 hrs